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The LeucoPatch® system in the
management of hard-to-heal diabetic foot
ulcers: study protocol for a randomised
controlled trial
Frances Game1* , William Jeffcoate2, Lise Tarnow3, Florence Day4, Deborah Fitzsimmons5 and Judith Jacobsen6
Abstract
Background: Diabetic foot ulcers are a common and severe complication of diabetes mellitus. Standard treatment
includes debridement, offloading, management of infection and revascularisation where appropriate, although healing
times may be long. The LeucoPatch® device is used to generate an autologous platelet-rich fibrin and leucocyte wound
dressing produced from the patient’s own venous blood by centrifugation, but without the addition of any
reagents. The final product comprises a thin, circular patch composed predominantly of fibrin together with
living platelets and leucocytes. Promising results have been obtained in non-controlled studies this system,
but this now needs to be tested in a randomised controlled trial (RCT). If confirmed, the LeucoPatch® may
become an important new tool in the armamentarium in the management of diabetic foot ulcers which are
hard-to-heal.
Methods: People with diabetes and hard-to-heal ulcers of the foot will receive either pre-specified good standard
care or good standard care supplemented by the application of the LeucoPatch® device.
The primary outcome will be the percentage of ulcers healed within 20 weeks. Healing will be defined as complete
epithelialisation without discharge that is maintained for 4 weeks and is confirmed by an observer blind to
randomisation group.
Discussion: Ulcers of the foot are a major source of morbidity to patients with diabetes and costs to health care
economies. The study population is designed to be as inclusive as possible with the aim of maximising the external
validity of any findings. The primary outcome measure is healing within 20 weeks of randomisation and the trial also
includes a number of secondary outcome measures. Among these are rate of change in ulcer area as a predictor of
the likelihood of eventual healing, minor and major amputation of the target limb, the incidence of infection and
quality of life.
Trial registration: International Standard Randomised Controlled Trial, ISRCTN27665670. Registered on 5 July 2013.
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Background
Diabetic foot ulcers
Diabetic foot ulcers (DFU), a common and severe com-
plication of diabetes mellitus, are currently the most
common chronic type of wound in Western industria-
lised countries [1]. Despite improved outcomes following
modern standard treatment, DFUs are still the predom-
inant reason for non-traumatic leg amputation in most
Western countries, amputation rates in patients with
diabetes being described as much as 15-fold higher than
those in non-diabetic populations [2].
Diabetic foot ulceration is the consequence of neuropathy
and micro- and macrovascular disease [3]. The syndrome is
frequently worsened by infection [4].
As all aspects of this multifactorial aetiology must be
taken into account, modern standard treatment includes
regular debridement, off-loading, treatment of infection,
revascularisation when appropriate, optimising metabolic
control and the treatment of any concomitant diseases, as
well as education about foot care and the provision of
appropriate footwear [5, 6].
If these treatment strategies are properly applied the
majority of chronic non-healing ulcers will heal, although
healing times may be prolonged [1].
The presence of a DFU is also associated with signifi-
cant reduction in health-related quality of life (HRQoL);
ulcer healing is associated with improved HRQoL [7, 8].
Growth factors and healing
Growth factors are involved throughout the healing process
[9–11]. At the cellular level growth factors mediate macro-
phage migration, neovascularisation, collagen synthesis,
fibroblast proliferation as well as epithelialisation [12–15].
Animal, as well as in-vitro studies, have shown positive
effects of platelet-derived growth factors on ulcer healing
[16, 17]. Platelets contain a range of potent growth factors.
These consist, among others, of platelet-derived growth fac-
tor (PDGF), transforming growth factor-β (TGF-β), epider-
mal growth factor (EGF) and vascular endothelial growth
factor (VEGF), which together exhibit different chemotac-
tic, mitogenic and proliferative properties.
The first clinical study evaluating the effect of platelet-
derived growth factors on ulcer healing was performed
by Knighton et al. in 1986 [18]. In this small, prospective,
randomised, blinded, placebo-controlled, cross-over study
the effect of a platelet-derived, wound-healing formula
(PDWHF) was evaluated. The frequency of complete
epithelialisation of ulcers was significantly higher in
PDWHF-treated patients when compared to controls
(87% versus 15%), and, after cross-over, complete epithelia-
lisation was achieved in the control group after
7.1 weeks [18]. In a case-series of 24 patients, Crovetti
et al. achieved sustained ulcer healing in eight patients
with chronic cutaneous ulcers, and ulcer area reduction in
another seven cases, after topical treatment with a platelet
gel [19].
In a retrospective cohort study, Margolis et al. estimated
the effectiveness of platelet releasate in the treatment of
diabetic neuropathic foot ulcers using the Curative Health
Services database including 120,000 patients with chronic
wounds. The analysis suggested that treatment with platelet
releasate was more effective than standard therapy, with
the most pronounced beneficial effect being seen in more
serious ulcers [20]. However, Stacey et al. found no effect
on the healing of chronic venous leg ulcers using lysed
platelets in a randomised, double-blind, placebo-controlled
study [21]. Neither could Senet et al. show any beneficial
effect on healing of chronic venous leg ulcers [22].
Since the study by Knighton et al., many methods for
producing platelet releasate, platelet gel and fibrin-platelet
suspensions have been developed. They are all quite com-
plex and all require the addition of different reagents, and
thus cannot by definition be characterised as purely
autologous products. The concentration and activation of
platelets in these products varies and, despite promising
early results, the need for confirmation in large, good-
quality randomised controlled trials (RCTs) remains [6].
LeucoPatch®
The LeucoPatch® device is a CE-marked, single-use
medical device used to generate an autologous platelet-
and leucocyte-rich fibrin wound dressing named the
LeucoPatch®. A LeucoPatch® is produced from the patient’s
own venous blood by centrifugation, but without the
addition of any reagents. The final product comprises a
thin, circular patch composed predominantly of fibrin
together with living platelets and leucocytes (Fig. 1).
The number of LeucoPatches® applied can be adjusted
to fit the individual wound. The yield of platelets is
close to 100% and varies minimally from patient to
patient. The content and release of growth factors of
this product is equal to, or higher, than other reported
preparations. The product differs from other autolo-
gous platelet products by containing a high concentra-
tion of fibrin as well as both platelets and leucocytes.
In an initial pilot study, promising beneficial effects on
ulcer healing after the application of the LeucoPatch®
were seen [23]. Following this, in an open, clinical multi-
centre study including 41 patients with hard-to-heal
DFUs (median ulcer duration of 40 weeks) an intention-
to-treat (ITT) analysis showed that 12 (32%) healed
within 12 weeks of once-weekly treatment and 22 (54%)
healed within 20 weeks. No safety issues were raised in
this trial [24]. This apparent beneficial effect now needs
to be tested in a RCT. If confirmed, the LeucoPatch®
may become an important new tool in the armamentar-
ium for the management of DFUs which are hard-to-heal.
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Aims
This study will demonstrate whether the application of
the LeucoPatch®, when used in addition to usual care in
a multidisciplinary, diabetes foot clinic setting, is super-
ior to usual care alone with regard to complete epithelia-
lisation of hard-to-heal DFUs which are not infected at
the time of randomisation. The Standard Protocol Items:
Recommendations for Interventional Trials (SPIRIT)
schedule is given in Fig. 2.
Methods
Design
This is a multicentre, multinational, observer-blind, ran-
domised controlled trial. Patients will be randomised 1:1
to the intervention or the usual-care arm.
Study setting and participants
Participants will be recruited from specialist diabetes foot
care clinics at sites in the UK, Denmark and Sweden.
Eligible participants will be people aged 18 years and
over who have diabetes complicated by one or more foot
ulcers. In addition, the following inclusion and exclusion
criteria will apply:
Inclusion criteria
 Eligible ulcers will be below the level of the malleoli,
excluding ulcers confined to the interdigital cleft
 Eligible ulcers will be hard-to-heal, meaning that the
cross-sectional area will decrease by less than 50%
during a 4-week run-in period
 The cross-sectional area of the index ulcer will be ≥
50 and ≤ 1000 mm2 at the end of the 4-week run-in
period
 At randomisation, the index ulcer will be clinically
non-infected according to the Infectious Diseases
Society of America (IDSA) criteria
 Either the Ankle-brachial Pressure Index (ABPI) in
the affected limb will be between 0.50 and 1.40 or
the dorsalis pedis pulse and/or the tibialis posterior
pulse will be palpable
 Glycosylated haemoglobin (HbA1c) level ≤ 108 mmol/
mol at screening
 Participants will have the capacity to understand
study procedures, and will be able to provide written
informed consent
Exclusion criteria
 Increase in cross-sectional area of the index ulcer
by ≥ 25% during the 4-week run-in period, or is either
smaller than 50 mm2 or larger than 1000 mm2 at the
end of that time
 Clinical signs of infection of the index ulcer or
reason to suspect that infection is present at
randomisation
 Revascularisation procedure in the affected limb
planned, or undertaken within the 4 weeks prior to
screening
 Treatment of foot ulcers with growth factors, stem
cells or equivalent preparation within the 8 weeks
prior to screening
 The need for continued use of negative-pressure
wound therapy
 Haemoglobin concentration < 105 g/L or 6.5 mmol/L
at screening
 Presence of sickle-cell anaemia, haemophilia,
thrombocytopenia (<100 × 109/L) or other clinically
significant blood dyscrasia
 Known potential infectivity of blood products,
including known HIV and hepatitis
 Dialysis or an estimated glomerular filtration rate
(GFR) (based on cystatin C or serum creatinine)
< 20 ml/min/1.73 m2
 Current treatment with cytotoxic drugs or with
systemically administered glucocorticoids or other
immunosuppressants. Likely inability to comply with
the need for weekly visits because of planned activity
 Participation in another interventional clinical foot
ulcer-healing trial within the 4 weeks prior to
screening
 Prior randomisation in this trial
Fig. 1 A LeucoPatch® post centrifugation
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 Judgement by the investigator that the patient does
not have the capacity to understand the study
procedures or to provide written informed consent
Sample size
Previous non-controlled LeucoPatch® outcome data sug-
gested a healing rate (intention-to-treat) of 54% during a
20-week follow-up period in a study population similar
to this study population. Outcome data from a matched
control group as well as from placebo/control groups in
other diabetic foot studies with inclusion and exclusion
criteria similar to these criteria indicate healing rates
between 27 and 32% at 20 weeks’ follow-up, although
some authors have reported healing rates below 10%.
A sample size for comparing two proportions with
Fleiss continuity correction, based on alpha = 0.05 and
beta = 80% and with an outcome rate in the control
group of 30% and an improvement of 18 percentage
points (i.e. to 48%) in the treatment group gives a
sample size of 250 evaluable patients. To allow for 30%
dropout a sample size of 350 randomised participants is
sought.
As there is uncertainty on both healing rates and
dropout rates, the Data Monitoring Committee (DMC)
will perform an interim based re-estimation of sample
size when 140 randomised patients (70 patients in each
group) have completed 20 weeks of follow-up. The sample
size re-estimation will be done by comparing 20 weeks’
healing proportions from two groups with Fleiss continuity
correction, based on two-sided alpha = 0.04 and beta = 80%,
on both the intention-to-treat (ITT) and per-protocol (PP)
populations.
Interventions
All participants will receive pre-specified good standard
care of their diabetic foot ulcers in a multidisciplinary
diabetes foot clinic setting, following international guide-
lines [5] as described in Table 1.
Fig. 2 Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) Checklist
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Participants randomised to the intervention group will, in
addition, receive a weekly application of the LeucoPatch®.
The LeucoPatch® is prepared by centrifuging one (for
ulcers ≤ 5 cm2) or two (for ulcers > 5 cm but ≤ 10 cm2) 18-
mL aliquots of the participant’s venous blood according to
the instructions for use. The centrifugation yields a tough
layer of fibrin, with viable leucocytes and platelets, and this
is applied directly to the wound surface using sterile for-
ceps. The wound is then covered with an inert primary
dressing, a secondary protective dressing and the ulcerated
area protected with appropriate off-loading.
Study visit schedule (Fig. 2)
After giving written informed consent participants will
be seen every 2 weeks during a 4-week run-in period to
confirm eligibility. Those fulfilling inclusion and exclu-
sion criteria at the end of the run-in period will be ran-
domised and receive study treatment once weekly for
20 weeks or until healing, whichever occurs first. When
a blinded observer has confirmed healing of the target
ulcer, the patient will be scheduled for two healing con-
firmatory visits within the next 4 weeks. If target ulcer
healing is confirmed by a blinded assessor at the 4-week
confirmatory visit, the participant will enter the follow-
up phase of the study, completing follow-up visits at 20
and 26 weeks post randomisation. If the target ulcer
remains unhealed after 20 weeks of treatment, the par-
ticipant will complete follow-up visits at 20 and 26 weeks
post randomisation.
An additional study visit 12 weeks after initial healing
and a telephone follow-up at 52 weeks after randomisa-
tion will be made to collect ulcer status (durability of
wound healing) and safety information.
Outcomes
Primary outcome
Comparison of the number (%) of hard-to-heal ulcers
that heal within 20 weeks following pre-specified good
standard care with the numbers healed following
standard care plus the topical application of LeucoPatch®
in a multidisciplinary diabetes foot clinic setting.
Healing will be assessed following any necessary de-
bridement and will be defined as complete epithelialisa-
tion, which is maintained for 4 weeks. Healing will be
confirmed both at the start and the end of the 4-week
period by an observer who is blind to randomisation
group. The date of healing will be that at which it was
first noted by the clinical researcher and confirmed by
an observer, blind to the intervention group.
Secondary effectiveness outcomes
Ulcer-related outcomes:
 Time (days) to healing by 20 weeks
 The incidence of healing within 12 and 26 weeks
 Change in ulcer area at 4, 12, 16, 20 and 26 weeks (as
compared to week 0), as assessed by acetate tracing
and digital images, measured by a blinded assessor
 Change in ulcer healing rate between the run-in
period and the first 4 weeks in the treatment period
 The incidence of secondary infection
 Number of days of systemic antibiotic therapy
administered for foot ulcer infection during the
20 weeks from randomisation
 Durability of wound healing 12 weeks after complete
wound healing
Patient-related outcomes:
 The incidence of major (above-ankle) amputation
affecting the target limb by 12, 20 and 26 weeks
 The incidence of major amputation affecting the
contralateral limb by 26 weeks
 The incidence of minor (below-ankle) amputation
affecting the target limb by 12, 20 and 26 weeks
 The incidence of minor amputation affecting the
contralateral limb by 26 weeks
 Quality-of-life measured as using the Short Form 12
questionnaire (SF-12) and EuroQol-5D questionnaire
(EQ-5D) at baseline, 12 and 20 weeks
 Pain as assessed by Visual Analogue Scale (VAS)
 Incidence of new anaemia
Patients enrolled in the study will be asked to keep a
patient diary to inform a health economic record by log-
ging information on:
 Consultations, mode and place of consultations with
health care professionals not scheduled for the
purpose of the study
 Usage of home help or home nursing
 Time spent travelling for consultations scheduled
and not scheduled for the purpose of the study
Table 1 Components of good standard wound care
• Formal assessment of ulcer and surrounding skin
• Provision of any necessary off-loading
• Debridement (i) sharp, (ii) other as appropriate (but excluding
the use of larvae)
• Appropriate dressing products
• Appropriate antibiotic therapy
• Nutrition and self care
• Optimal glycaemic control
• Revascularisation if deemed clinically necessary
• Continued close observation
Game et al. Trials  (2017) 18:469 Page 5 of 8
 Direct cost of travelling for consultations scheduled
and not scheduled for the purpose of the study
 Days off work due to the foot ulcers
 Assistance from non-health care professionals due
to foot ulcers
Centres enrolled in the study will be asked to log:
 Average time per staff category/grade spent per
patient administrating standard care and standard
care with the LeucoPatch® used in addition
 Average salary and working hours for staff categories
involved in the study
 Current medications, dressings and devices used for
the treatment of all patients included in the study as
detailed under the study visit schedule
Health economic evaluation
Specific objectives are to establish the costs of the
LeucoPatch® in addition to usual care and assess the
cost-effectiveness of the LeucoPatch® in addition to
usual care versus usual care alone. The perspective of
the health care system (e.g. UK NHS) and personal
social services, with consideration of a broader societal
perspective which considers the impact on patients
and their families will be taken. As the study involves
three countries, appropriate consideration, following
good practice guidelines [25], will be taken to ensure
that resources and costs are appropriately calculated
given the potential for differences in resource use
between countries. Costs associated with the interven-
tion will be determined by calculating the cost of staff
time, materials and other resources involved in providing
the intervention. These will be compared with changes in
the number of visits to general practitioners, hospital, pre-
scribed medication, and social services’ contacts in the
intervention and control groups during the investigation.
In addition, should data allow, the costs incurred by
patients and their families (e.g. travel, time off work) will
be calculated. The costs will be compared with the
outcomes generated and a series of incremental cost-
effectiveness ratios computed, including a cost/quality-ad-
justed life year analysis, based on changes in EQ-5D. A
series of one-way sensitivity analyses will be undertaken to
determine the extent to which baseline findings change in
light of parameter variation and a probabilistic sensitivity
analysis undertaken to determine the extent to which the
intervention can be regarded as representing value for
money. Should evidence be found from the within-trial
analysis on the short-term effectiveness of LeucoPatch® in
addition to usual care compared to usual care alone, a de-
cision analytical model will be developed in order to assess
cost-effectiveness over a longer time horizon.
Patients enrolled in the study will be asked to keep a
patient diary to inform a health economic record by log-
ging information on:
 Consultations, mode and place of consultations with
health care professionals not scheduled for the
purpose of the study
 Usage of home help or home nursing
 Time spent travelling for consultations scheduled
and not scheduled for the purpose of the study
 Direct cost of travelling for consultations scheduled
and not scheduled for the purpose of the study
 Days off work due to the foot ulcers
 Assistance from non-health care professionals due
to foot ulcers
Centres enrolled in the study will be asked to log:
 Average time per staff category/grade spent per
patient administrating standard care and standard
care with the LeucoPatch® used in addition
 Average salary and working hours for staff categories
involved in the study
 Current medications, dressings and devices used for
the treatment of all patients included in the study as
detailed under the study visit schedule
Safety and tolerability measures
Safety will be assessed in relation to adverse events (AEs),
serious adverse events (SAEs), adverse device effects
(ADEs) and serious adverse device effects (SADEs).
AEs will be assessed for relatedness to the device, in-
cluding device failures, errors or misuse of the device.
For the purposes of assessing relatedness, the ‘device’ is
defined as the three components of the CE-marked
LeucoPatch® system, that is:
 The LeucoPatch® device
 The LeucoPatch® needle holder
 Centrifuge insert
No adverse events are expected as a result of the use
of the device.
Analyses
All analyses will be completed on both the ITT and the
PP populations. The primary analysis for outcome will
be a logistic regression for the proportions of patients
healed within 20 weeks taking into account ulcer area,
ulcer depth and ABPI.
All secondary variables will be presented using
appropriate descriptive statistics and analysed on the
basis of the level of measures and the distribution of
scores (where appropriate). Analyses will include
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survival analysis for time to healing and general linear
models for difference in change of pain score; with
EQ-5D and SF-12 data presented in line with the con-
ventions for these tools.
Cost-effectiveness and cost-utility analysis will be per-
formed based on the cost-related endpoints collected in
the study.
Randomisation and blinding
Internet-based treatment assignment will be determined
by a computer-generated random code using random
permuted blocks of randomly varying size, created by
the Nottingham Clinical Trials Unit in accordance with
their Standard Operating Procedures. Trial participants
will be allocated with equal probability to each treatment
arm with stratification by centre, and by ulcer area (≤
100 mm2 versus > 100 mm2).
The use of the LeucoPatch® in the intervention group
will be apparent to both the participant and health profes-
sionals involved in the care of their foot ulcer. The pri-
mary outcome will, however, be confirmed by observers
blind to randomisation group and all other outcomes will
be analysed by researchers blind to randomisation group.
Discussion
Ulcers of the foot are a major source of morbidity to
patients with diabetes and costs to health care economies.
Whilst clinicians have a plethora of topical and systemic
treatments to choose from, few have been subjected to
rigorous evaluation in a blinded randomised trial [6].
Early studies with growth-factor-based [18] methods
for producing platelet releasate, platelet gel or fibrin-
platelet suspensions have been complex and/or required
large blood volumes. The LeucoPatch® device, which pro-
duces a patch of fibrin platelets and leucocytes from
relatively small volumes of the patient’s venous blood, over-
comes many of these problems. Early pilot data suggest im-
proved healing in a group of patients with diabetes with
hard-to-heal foot ulcers.
The study population is designed to be as inclusive as
possible with the aim of maximising the external validity
of any findings. Thus, the intention is to include a large
percentage of people with diabetes complicated by ulcer-
ation of the foot, including those with all but the most
severe peripheral arterial or renal disease. Whilst patients
cannot be included if the ulcer is clinically infected at the
point of randomisation, should secondary infection be de-
tected during follow-up the patient will not be withdrawn.
The population of interest and likely to benefit the most
are those who do not heal more than 50% in 4 weeks of
observation during best standard care (Table 1), the ‘hard-
to-heal’ group. It is for this reason that an initial 4-week
observation period is scheduled. Whilst it is not possible
to blind either the participant or their usual-care team to
the allocated arm of the study, the primary outcome
measure (clinical healing) will be confirmed by an obser-
ver blind to allocated treatment to reduce the possibility
of bias.
The primary outcome measure is healing within 20 weeks
of randomisation and the trial also includes a number of
secondary outcome measures. Principal among these are
rate of change in ulcer area as a predictor of the likelihood
of eventual healing, minor and major amputation of the tar-
get limb, the incidence of infection and quality of life.
Trial status
Participant recruitment commenced in August 2013. As
of 31 May 2017, 595 participants consented to join the
study, and of these 269 participants were randomised.
Three hundred and twenty-six participants did not proceed
to randomisation. Recruitment has now closed.
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